This post may refer to COVID-19
To access official information about the coronavirus, access CDC - Centers for Disease Control and Prevention.
www.reuters.com
Moderna to seek U.S., EU emergency authorization Monday after COVID-19 vaccine 94.1% effective
Moderna Inc said it will apply for U.S. and European emergency authorization of its COVID-19 vaccine on Monday based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns.
Health
(Reuters) - Moderna Inc said it will apply for U.S. and European emergency authorization of its COVID-19 vaccine on Monday based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns.
It also reported a 100% success rate in preventing severe cases. The filing sets Moderna’s product up to be the second vaccine likely to receive U.S. emergency use authorization this year.
“We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it,” Moderna Chief Medical Officer Dr. Tal Zaks said in a telephone interview. “We expect to be playing a major part in turning around this pandemic.”
Zaks said he was emotional after seeing the 94.1% result over the weekend: “It was the first time I allowed myself to cry. At this level of effectiveness, when you just do the math of what it means for the pandemic that’s raging around us, it’s just overwhelming.”
Moderna’s announcement follows news from Pfizer Inc and German partner BioNTech SE that their vaccine, which also uses a new technology called synthetic messenger RNA (mRNA), was 95% effective. Pfizer has applied for emergency use authorization, putting it about a week ahead of Moderna.